Santen Pharmaceutical Co., Ltd. provided consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27. On IFRS basis, the company expects revenue of ¥273,000 million, operating profit of ¥32,000 million, net profit for the year of ¥22,400 million and basic earnings per share of ¥61.24.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,644 JPY | +0.95% | +3.33% | +16.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.98% | 3.76B | |
+40.73% | 739B | |
+31.51% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.55% | 240B | |
+9.52% | 210B | |
-5.36% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024